Skip to content

Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy (HRT)

Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy: A Randomized, Placebo-controlled Prospective Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00668603
Acronym
SYMPTOM
Enrollment
160
Registered
2008-04-29
Start date
2005-08-31
Completion date
2008-03-31
Last updated
2016-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Postmenopausal Vasomotor Symptoms

Keywords

Postmenopausal vasomotor symptoms, Hot flush, Vascular function, Cardiac function, Cardiovascular risk factor

Brief summary

Recent large randomized, placebo-controlled studies assessing the health effects of HT question the overall benefits of long term HT, especially with respect to cardiovascular disease. However, recently menopausal women with severe hot flushes were mostly excluded from these trials. This was unfortunate since vasomotor symptoms may reflect different vascular sensitivity to estrogen or its deficiency, and therefore, the vascular responses to HT in women with and without hot flushes can differ. Aims of the present project are 1. to compare vascular, cardiac and sympathetic function in recently menopausal women with or without severe vasomotor symptoms 2. in a randomized placebo controlled clinical trial investigate vascular response to oral and trans-dermal HT.

Detailed description

We recruit 160 healthy postmenopausal women between ages 48-55. Eighty women must have severe vasomotor symptoms (at least seven severe or moderate hot flush attacks per day) whereas 80 comparators must be symptomless (no hot flushes). Thorough vascular function and risk factor assessments will be done, including clinical assessment of autonomic nervous system, endothelial function measurements, 24-hour ECG and blood pressure evaluation, and lipid and various other vascular surrogate marker measurements. In the first part of the study we compare these baseline measurements between women with or without severe vasomotor symptoms. In the second part of the study the women are randomized to receive placebo, oral estrogen, oral estrogen plus progestin or transdermal estrogen for 6 months. After the treatments the baseline assessments are repeated.

Interventions

DRUG17-b-estradiol

2mg oral daily for 6 months

DRUG17-b-estradiol + medroxyprogeterone acetate

2mg E2 + 5mg MPA daily for 6 months

DRUG17-b-estradiol hemihydrate

1 mg skin gel daily for 6 months

DRUGplacebo pill + gel

placebo daily for 6 months

Sponsors

Päivikki and Sakari Sohlberg Foundation, Finland
CollaboratorOTHER
Emil Aaltonen Foundation
CollaboratorOTHER
Finnish Medical Foundation
CollaboratorNETWORK
University of Helsinki
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
48 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Postmenopausal women between ages 48-55 * Minimum of 6 months and maximum of 36 months from last menstrual period * Postmenopausal status of these women will be confirmed by level of FSH that should exceed 30 U/l * Eighty women must have severe vasomotor symptoms (at least seven severe or moderate hot flush attacks per day) whereas eighty comparators must be symptomless

Exclusion criteria

* smoking * hysterectomy * dyslipidemia * overt hypertension (blood pressure \> 140/90) * diabetes * any regular medication * HT in the previous 3 months * body mass index over 27

Design outcomes

Primary

MeasureTime frame
Vascular function0 and 6 months

Secondary

MeasureTime frame
Cardiac and sympathetic function0 and 6 months

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026